Isofol Medical AB (publ)

OM:ISOFOL Stock Report

Market Cap: SEK 193.8m

Isofol Medical Management

Management criteria checks 1/4

Isofol Medical's CEO is Petter Lindqvist, appointed in Jan 2024, has a tenure of 1.33 years. total yearly compensation is SEK2.77M, comprised of 60.4% salary and 39.6% bonuses, including company stock and options. directly owns 0.04% of the company’s shares, worth SEK78.40K. The average tenure of the management team and the board of directors is 1.3 years and 1.3 years respectively.

Key information

Petter Lindqvist

Chief executive officer

SEK 2.8m

Total compensation

CEO salary percentage60.39%
CEO tenure1.3yrs
CEO ownership0.04%
Management average tenure1.3yrs
Board average tenure1.3yrs

Recent management updates

Recent updates

We're Interested To See How Isofol Medical (STO:ISOFOL) Uses Its Cash Hoard To Grow

Jul 12
We're Interested To See How Isofol Medical (STO:ISOFOL) Uses Its Cash Hoard To Grow

An Intrinsic Calculation For Isofol Medical AB (publ) (STO:ISOFOL) Suggests It's 45% Undervalued

May 18
An Intrinsic Calculation For Isofol Medical AB (publ) (STO:ISOFOL) Suggests It's 45% Undervalued

Here's Why We're Not At All Concerned With Isofol Medical's (STO:ISOFOL) Cash Burn Situation

Nov 09
Here's Why We're Not At All Concerned With Isofol Medical's (STO:ISOFOL) Cash Burn Situation

Is Isofol Medical (STO:ISOFOL) In A Good Position To Deliver On Growth Plans?

May 12
Is Isofol Medical (STO:ISOFOL) In A Good Position To Deliver On Growth Plans?

Market Sentiment Around Loss-Making Isofol Medical AB (publ) (STO:ISOFOL)

Apr 08
Market Sentiment Around Loss-Making Isofol Medical AB (publ) (STO:ISOFOL)

Isofol Medical (STO:ISOFOL) Has Gifted Shareholders With A Fantastic 127% Total Return On Their Investment

Mar 03
Isofol Medical (STO:ISOFOL) Has Gifted Shareholders With A Fantastic 127% Total Return On Their Investment

We Think Isofol Medical (STO:ISOFOL) Needs To Drive Business Growth Carefully

Jan 10
We Think Isofol Medical (STO:ISOFOL) Needs To Drive Business Growth Carefully

CEO Compensation Analysis

How has Petter Lindqvist's remuneration changed compared to Isofol Medical's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

-SEK 49m

Dec 31 2024SEK 3mSEK 2m

-SEK 43m

Compensation vs Market: Petter's total compensation ($USD287.62K) is about average for companies of similar size in the Swedish market ($USD282.20K).

Compensation vs Earnings: Insufficient data to compare Petter's compensation with company performance.

CEO

Petter Lindqvist

1.3yrs
Tenure
SEK 2,767,000
Compensation

Mr. Petter Segelman Lindqvist serves as Chief Executive Officer of Isofol Medical AB (publ) since January 09, 2024. He served as Chief Executive Officer of Hamlet BioPharma AB (publ) (formerly known as Ham...

Leadership Team

NamePositionTenureCompensationOwnership
Petter Lindqvist
Chief Executive Officer1.3yrsSEK 2.77m0.040%
SEK 78.4k
Roger Tell
Chief Medical Officer1.3yrsSEK 67.00kno data
Margareta Hagman
Chief Financial Officerless than a yearno data0.025%
SEK 48.0k
1.3yrs
Average Tenure

Experienced Management: ISOFOL's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Jan-Eric Österlund
Independent Chairman1.3yrsSEK 773.00k0.40%
SEK 768.0k
Sten Nilsson
Independent Director1.3yrsSEK 247.00k0.0019%
SEK 3.7k
Lars Lind
Independent Director1.3yrsSEK 421.00k0.25%
SEK 488.8k
Heinz-Josef Lenz
Member of Advisory Boardless than a yearno datano data
Alain Herrera
Independent Director1.3yrsSEK 319.00kno data
Sebastian Stintzing
Member of Advisory Boardless than a yearno datano data
Helena Taflin
Independent Director1.3yrsSEK 247.00k0.15%
SEK 300.0k
Takayuki Yoshino
Member of Advisory Boardless than a yearno datano data
1.3yrs
Average Tenure
75yo
Average Age

Experienced Board: ISOFOL's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/22 17:33
End of Day Share Price 2025/05/22 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Isofol Medical AB (publ) is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ulrik TrattnerCarnegie Investment Bank AB
Ole-Andreas KrohnDNB Markets
David MartinssonDNB Markets